OncoMatch

OncoMatch/Clinical Trials/NCT06710249

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

Is NCT06710249 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for glioblastoma.

Phase 2RecruitingPeter SiesjöNCT06710249Data as of May 2026

The objective of this clinical trial is to explore the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, and SPC® flakes , hydrothermically processed oats, on cerebral edema with clinical symptoms in participants with brain tumors. The primary questions the trial seeks to answer are: * Can Salovum® and SPC® flakes have effect on clinical symptoms of tumor-induced cerebral edema? * Can Salovum® and SPC® flakes induce regression of radiological edema in tumor-induced cerebral edema Additionally, the study will investigate the impact of Salovum® and SPC® flakes in steroid refractory, steroid naïve cerebral edema and type of barin tumor Researchers will: Evaluate edema change from baseline by MRI after 14 days Evaluate neurological and cognitive symptoms Register dose of steroid medications Participants will: * Ingest Salovum® 11g three times daily for 14 days, thereafter tapered during 14 days * Ingest SPC® flakes 1g/kg daily from day 7

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Performance status

WHO/ECOG 0–2

WHO ECOG performance status 0-2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify